IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 6111 
Small font sizeDefault font sizeIncrease font size
Navigate Here
    Next article
    Previous article
    Table of Contents

Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded258    
    Comments [Add]    

Recommend this journal


Year : 2008  |  Volume : 40  |  Issue : 2  |  Page : 84-86

Effect of erythromycin and rifampicin on monoethylglycinexylidide test

1 Govt. College of Pharmacy, Vidyanagar, Karad, (MS) - 415 124, India
2 Satara College of Pharmacy, Plot No 1539, New Add MIDC, Degaon, Satara, Maharashatra - 415 004, India

Correspondence Address:
Remeth Jacky Dias
Satara College of Pharmacy, Plot No 1539, New Add MIDC, Degaon, Satara, Maharashatra - 415 004
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0253-7613.41044

Rights and Permissions

Background: The dynamic liver function test based on the hepatic conversion of lidocaine to monoethylglycinexylidide (MEGX) provides a direct measure of the actual functional state of the liver. Cytochrome P450 (CYP) 3A4 has been proposed as the main CYP isoform responsible for MEGX formation. The concomitant use of either CYP3A4 inducer rifampicin or CYP3A4 inhibitor erythromycin may influence the results of MEGX test. Hence, the objective of this study was to evaluate the effect of a CYP3A4 inhibitor erythromycin and inducer rifampicin on the MEGX test. Materials and Methods: The study included 20 healthy male volunteers whose routine laboratory tests were normal. As per study protocol, MEGX test was carried out in all the participants after an overnight fast. All the participants were given 1 mg/kg lidocaine dose intravenously and MEGX concentration at 30 and 60 min after IV dose was measured using HPLC. These MEGX values served as control values. Ten subjects received 600 mg/day erythromycin orally for six days while remaining ten participants received 600 mg/day rifampicin orally for six days. On the sixth day, MEGX test was carried out two hours after the last dose. Result: Rifampicin increased the mean plasma concentration of MEGX 30 from 93.94 26.31 to 98.54 24.94 g/ml (P = 0.085) and MEGX 60 from 134.34 35.42 to 136.36 33.14 g/ml (P = 0.051). Erythromycin lowered the serum concentration of MEGX 30 from 101.37 39.39 to 96.67 36.09 g/ml (P = 0.128) and MEGX 60 from 142.52 42.65 to 138.98 40.23 g/ml (P = 0.159). Conclusion: It can be concluded from this study that the MEGX test is not affected by concomitant administration of CYP3A4 modifiers rifampicin and erythromycin.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow